Pfizer shares experienced a healthy 7.71% gain today as the company announced a patent victory on its biggest selling drug. This stock is technically interesting because it gapped up toward the combined resistance of the October highs and the 200 DMA. These levels have prevented the bulls from pushing the price higher on several previous occasions, and we believe that this may be the case again.


You May Also Like

Related Analysis
  1. Stock Analysis

    Weight Watchers Still Too Pricey at 52-Week Low

  2. Stock Analysis

    Could Greece Find A Safe Haven In U.S. Markets?

  3. Stock Analysis

    Why ConAgra Is Finally Dumping Private-Label Goods

  4. Stock Analysis

    DryShips Cashes Out of Tanker Business

  5. Savings

    The Pros and Cons of Buying on Amazon

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!